CN107998274A - One seed ginseng wheat polysaccharide formulation and preparation method thereof - Google Patents
One seed ginseng wheat polysaccharide formulation and preparation method thereof Download PDFInfo
- Publication number
- CN107998274A CN107998274A CN201810075941.XA CN201810075941A CN107998274A CN 107998274 A CN107998274 A CN 107998274A CN 201810075941 A CN201810075941 A CN 201810075941A CN 107998274 A CN107998274 A CN 107998274A
- Authority
- CN
- China
- Prior art keywords
- medicinal material
- ophiopogon
- material slag
- ginseng
- red ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 53
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 53
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 53
- 241000209140 Triticum Species 0.000 title claims abstract description 40
- 235000021307 Triticum Nutrition 0.000 title claims abstract description 40
- 241000208340 Araliaceae Species 0.000 title claims abstract description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 36
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000009472 formulation Methods 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 241001448424 Ophiopogon Species 0.000 claims abstract description 41
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 41
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 40
- 239000002893 slag Substances 0.000 claims abstract description 38
- 238000000605 extraction Methods 0.000 claims abstract description 31
- 235000019441 ethanol Nutrition 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000012141 concentrate Substances 0.000 claims abstract description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000001556 precipitation Methods 0.000 claims abstract description 16
- 238000010992 reflux Methods 0.000 claims abstract description 13
- 238000005119 centrifugation Methods 0.000 claims abstract description 12
- 239000012153 distilled water Substances 0.000 claims abstract description 10
- 238000007598 dipping method Methods 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000002244 precipitate Substances 0.000 claims abstract description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 7
- 238000004064 recycling Methods 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 239000012535 impurity Substances 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 abstract description 8
- 238000001914 filtration Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 2
- 230000008719 thickening Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000033065 inborn errors of immunity Diseases 0.000 description 12
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 6
- 230000008944 intestinal immunity Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241001591005 Siga Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DQYACEDUQHWXQZ-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-2)-O-<alpha-L-arabinopyranosyl-(1-3)>-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O DQYACEDUQHWXQZ-UHFFFAOYSA-N 0.000 description 1
- FHKHGNFKBPFJCB-UHFFFAOYSA-N (25S)-ruscogenin 1-O-<alpha-L-rhamnopyranosyl(1->2)><beta-D-xylopyranosyl(1->3)>-beta-D-fucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(C)C(O)C1OC1OCC(O)C(O)C1O FHKHGNFKBPFJCB-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101710116034 Immunity protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FHKHGNFKBPFJCB-LYLKFOBISA-N Ophiopogonin D Chemical compound O([C@H]1[C@@H](O)[C@@H](C)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O FHKHGNFKBPFJCB-LYLKFOBISA-N 0.000 description 1
- NJYZGIOABZGGBB-UHFFFAOYSA-N Ophiopogonin D' Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(O)C(OC8OCC(O)C(O)C8OC9OC(C)C(O)C(O)C9O)C7O NJYZGIOABZGGBB-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- IDGCVTONMQMXPU-JHZREZMDSA-N ophiopogonin D Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@@H](O)C[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O)[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C IDGCVTONMQMXPU-JHZREZMDSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses seed ginseng wheat polysaccharide formulation and preparation method thereof, which comprises the following steps：Red ginseng and ophiopogon are separately added into alcohol dipping, then heating and refluxing extraction, recycling extraction residue, dries in drier, red ginseng medicinal material slag and ophiopogon medicinal material slag is prepared；Red ginseng medicinal material slag and ophiopogon medicinal material slag are mixed, distilled water is added and is extracted, extraction is twice；Merge extracting solution by its thickening filtration, concentrate is prepared；Absolute ethyl alcohol is added in the concentrate being prepared, is stood overnight, precipitation is collected by centrifugation, after being washed successively with absolute ethyl alcohol, acetone, is centrifuged；Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying, obtain ginseng wheat polysaccharide pulvis.This polysaccharide formulation preparation process is simple, of low cost, is that Shenmai injection extraction residue is reused, has good immunological enhancement.
Description
Technical field
The invention belongs to technical field of medicine, specifically, is related to seed ginseng wheat polysaccharide formulation and preparation method thereof.
Background technology
The dry root of ginseng system araliaceae ginseng plant's ginseng, is perennial herb, property happiness is shady and cool, is distributed mainly on black
In the northern remote mountains in the provinces such as Longjiang, Jilin, Liaoning and Hebei province, existing mostly artificial cultivation.It is dry after steaming that red ginseng is ginseng
Dry and root lotus, are the cooked of ginseng.Its is sweet in flavor, slight bitter, warm-natured, and returns spleen, lung, the heart channel of Hang-Shaoyin, tool reinforce vital energy, veins takes off admittedly,
The work(of nourishing qi to stop.Red ginseng polysaccharide is one of important component of red ginseng, and research shows that red ginseng polysaccharide has necessarily clear in vitro
Except free radical and antioxidation.Modern pharmacology research finds that red ginseng acidic polysaccharose (RGAP) has antifatigue, improvement climacteric
Many effects such as phase syndrome, AIDS virus (HIV) hyperplasia that suppresses, delaying aging, anticancer and adjusting immune function.Have been reported that
Point out that red ginseng polysaccharide can significantly improve the immune function of hypoimmunity mice, hence it is evident that improve hypoimmunity mice immunocyte because
The generation of son.
Ophiopogon derives from the meat stem tuber of Ophiopogon plant ophiopogon, medicinal to have effects that quench one's thirst of promoting the production of body fluid, moisten the lung and relieve the cough.
Ophiopogon often with other drug matchings, for controlling for dryness of the lung dry cough, injury thirst, vexed insomnia, Heat Diabetes, dry constipation of intestines etc.
Treat.Ophiopogonpolysaccharide is one of important component of ophiopogon, is mainly made of monose and oligosaccharide substance.Modern study is found, is joined
Wheat polysaccharide has the pharmacological action such as anti-oxidant, anti-inflammatory, hypoglycemic.There is the chest that document report ophiopogonpolysaccharide can dramatically increase young rat
Gland, spleen weight, can also increase the phagocytic activity of mouse reticuloendothelial system, improve haemolysis cellulose content in mice serum, hence it is evident that
Improve its immunocompetence.
Shenmai injection is formed by red ginseng and two taste Chinese prescription of ophiopogon, comes from ancient prescription Shengmai Yin.Red ginseng reinforces vital energy, is multiple
Arteries and veins prevent prolapse, nourishing qi to stop, ophiopogon Yin-nourishing and body fluid promoting, moistening lung clears away heart-fire, the two compatibility reinforcing both QI and YIN, negative and positive alternate, have QI invigorating prevent prolapse,
The effect of nourishing Yin and promoting production of body fluid and raw arteries and veins.Shenmai injection is widely used in the shock for the treatment of type of deficiency of both QI and YIN, coronary heart disease, viral cardiac muscle
The disease of cardiovascular systems such as inflammation, chronic cardiopulmonary disease, agranulocytosis, can improve the immunity function of tumour patient, with chemotherapeutic
When thing shares, there is certain synergistic effect, and the toxicity caused by chemotherapeutics can be reduced.1998, Shenmai injection
It is put into " Chinese patent drug of national emergency treatment of hospitals of Chinese medicine indispensability ".
Shenmai injection possesses wide market in China, but Shenmai injection is extracted by 90% ethanol, it is led
Want component for ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ophiopogonin D, ophiopogonin D ', methyl ophiopogon dihydro
7 kinds of components of flavone A and methyl ophiopogon flavanone, do not use red ginseng and the polysaccharide component in ophiopogon, and join wheat
The directly discharge of the production waste material of parenteral solution not only pollutes environment, but also also results in the direct waste of cost.
The content of the invention
In view of this, the present invention is directed to the problem of above-mentioned, there is provided seed ginseng wheat polysaccharide formulation and preparation method thereof.
In order to solve the above-mentioned technical problem, the invention discloses the preparation method of a seed ginseng wheat polysaccharide formulation, including it is following
Step：
Step 1, ethanol removal of impurities：Red ginseng and ophiopogon are separately added into alcohol dipping, then heating and refluxing extraction, red ginseng extraction
6 times, ophiopogon extracts 2 times, is extracted every time with 3 times of amount alcohol refluxs；Recycling extraction residue, dries in drier, is prepared
Red ginseng medicinal material slag and ophiopogon medicinal material slag；
Step 2, the contracting of water concentrate：Red ginseng medicinal material slag and ophiopogon medicinal material slag are mixed, distilled water is added and is extracted, extraction two
It is secondary；Merge extracting solution and be concentrated into 1/20 volume, filter, concentrate is prepared, it is spare；
Step 3, alcohol precipitation：Absolute ethyl alcohol is added in the concentrate that step 2 is prepared, 4 DEG C stand overnight, and are collected by centrifugation
Precipitation, after being washed successively with absolute ethyl alcohol, acetone, centrifuges；
Step 4, be freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying,
Obtain ginseng wheat polysaccharide pulvis.
Further, the volume fraction of the ethanol in the step 1 is 70%-90%；Extraction time is 1.5h-2.5h.
Further, the mass ratio of the red ginseng medicinal material slag in the step 2 and ophiopogon medicinal material slag is 1:1；The red ginseng medicine
The solid-liquid ratio (g/ml) of the gross mass and distilled water of material slag and ophiopogon medicinal material slag is 1:20-1:40；Water temperature raising degree is 60-100 DEG C,
It is 0.5-1.5h that each water, which carries the time,.
Further, the volume ratio of the concentrate in the step 3 and absolute ethyl alcohol is 1:2-1:6.
The invention also discloses a kind of ginseng wheat polysaccharide formulation being prepared by above-mentioned preparation method.
Compared with prior art, the present invention can be obtained including following technique effect：
1) waste material that the obtained polysaccharide formulation of the present invention belongs to for Shenmai injection recycles, Shenmai injection
Production can produce substantial amounts of production discarded object, the extraction that substantial amounts of extraction ginseng wheat polysaccharide can be collected into by resource reclaim is former
Material, takes full advantage of resource, substantially reduces the cost of production ginseng wheat polysaccharide formulation.This polysaccharide formulation is of low cost, possesses very strong
Economic benefit.
2) preparation of the invention only needs electric jacket (or remaining heating equipment), low speed centrifuge, drying box and rotation
The underlying instruments such as evaporimeter, simple and reliable process is convenient and easy, and instrument is conveniently purchased, no site requirements；Related chemistry reagent is
Ethanol and acetone, are recyclable chemical reagent, and the rate of recovery can reach more than 95%, of low cost, and without dirt
Contaminate thing to produce, environment protection health.
3) present invention is experimentally verified that the polysaccharide extract rate of gained polysaccharide Aqueous extracts is 31%, and obtained polysaccharide formulation is more
Sugared content is up to 62.8%.
4) present invention shows through pharmacodynamic study, be able to can be remarkably reinforced as a kind of immunopotentiator using this product
Hypoimmunity mice thymus gland, index and spleen index, adjust its intestinal flora, improve the intestinal immunity of hypoimmunity mice, have good
Good immunological enhancement.
Certainly, implement any of the products of the present invention and it is not absolutely required to reach all the above technique effect at the same time.
Brief description of the drawings
Attached drawing described herein is used for providing a further understanding of the present invention, forms the part of the present invention, this hair
Bright schematic description and description is used to explain the present invention, does not form inappropriate limitation of the present invention.In the accompanying drawings：
Fig. 1 is influence of the present invention ginseng wheat polysaccharide powder to hypoimmunity mice index and spleen index, different alphabetical expression groups in figure
Between there is otherness, P ＜ 0.01.
Embodiment
Carry out the embodiment that the present invention will be described in detail below in conjunction with embodiment, thereby to the present invention how application technology hand
Section solves technical problem and reaches the process of realizing of technical effect to fully understand and according to this implement.
The invention discloses the preparation method of a seed ginseng wheat polysaccharide formulation, comprise the following steps：
Step 1, ethanol removal of impurities：Heated after red ginseng is added the alcohol dipping that volume fraction is 70%-90% respectively with ophiopogon
Refluxing extraction, red ginseng extract 6 times, and ophiopogon extracts 2 times, every time with 3 times of amount 70%-90% alcohol reflux extractions 1.5h-2.5h；Return
Extraction residue is received, is dried in drier, red ginseng medicinal material slag and ophiopogon medicinal material slag is prepared；
Step 2, the contracting of water concentrate：By red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1：1 (w/w) ratio mixes, and will distill
Water is according to solid-liquid ratio 1:20-1:40th, 60-100 DEG C of temperature, twice, each 0.5-1.5h, merges concentrate to former extracting solution for extraction
The 1/20 of volume, filtration are spare；
Step 3, alcohol precipitation：The 2-6 times of absolute ethyl alcohol (V/V) measured is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation,
After being washed successively with absolute ethyl alcohol, acetone, centrifuge；
Step 4：It is freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying,
Obtain ginseng wheat polysaccharide pulvis.
Embodiment 1
The preparation method of one seed ginseng wheat polysaccharide formulation, comprises the following steps：
Step 1, ethanol removal of impurities：It is heated to reflux after 100g red ginsengs are added 90% (V/V) alcohol dipping respectively with 100g ophiopogons
Extraction, red ginseng extract 6 times, ophiopogon extract 2 times, every time with 3 times amount 90% alcohol refluxs extract 2 it is small when；Recycling extraction residue, in
Dried in drier；
Step 2, the contracting of water concentrate：By two kinds of medicinal material residues according to 1：1 (w/w) ratio mixes, i.e., by distilled water according to feed liquid
Than 1：30th, 90 DEG C of temperature, twice, each 1h, merges concentrate to the 1/20 of former extracting liquid volume, filtration is spare for extraction；
Step 3, alcohol precipitation：The absolute ethyl alcohol (V/V) of 4 times of amounts is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation, according to
It is secondary washed with absolute ethyl alcohol, acetone after, centrifuge；
Step 4：It is freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying,
Obtain ginseng wheat polysaccharide pulvis.
Embodiment 2
The preparation method of one seed ginseng wheat polysaccharide formulation, comprises the following steps：
Step 1, ethanol removal of impurities：It is heated to reflux carrying after red ginseng is added the alcohol dipping that volume fraction is 70% respectively with ophiopogon
Take, red ginseng extract 6 times, ophiopogon extract 2 times, every time with 3 times amount 70% alcohol refluxs extract 2.5 it is small when；Recycling extraction residue, in
Dried in drier, red ginseng medicinal material slag and ophiopogon medicinal material slag is prepared；
Step 2, the contracting of water concentrate：By red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1：1 (w/w) ratio mixes, and will distill
Water is according to solid-liquid ratio 1:20th, 100 DEG C of temperature, are extracted twice, each 0.5h, merging concentrate to the 1/20 of former extracting liquid volume,
Filter spare；
Step 3, alcohol precipitation：The absolute ethyl alcohol (V/V) of 2 times of amounts is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation, according to
It is secondary washed with absolute ethyl alcohol, acetone after, centrifuge；
Step 4：It is freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying,
Obtain ginseng wheat polysaccharide pulvis.
Embodiment 3
The preparation method of one seed ginseng wheat polysaccharide formulation, comprises the following steps：
Step 1, ethanol removal of impurities：It is heated to reflux carrying after red ginseng is added the alcohol dipping that volume fraction is 90% respectively with ophiopogon
Take, red ginseng extracts 6 times, and ophiopogon extracts 2 times, every time with 3 times of amount 90% alcohol reflux extraction 1.5h；Recycling extraction residue, Yu Gan
Dried in dry device, red ginseng medicinal material slag and ophiopogon medicinal material slag is prepared；
Step 2, the contracting of water concentrate：By red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1：1 (w/w) ratio mixes, and will distill
Water is according to solid-liquid ratio 1:40th, temperature 60 C, twice, each 1.5h, merges concentrate to the 1/20 of former extracting liquid volume, filters for extraction
Cross spare；
Step 3, alcohol precipitation：The absolute ethyl alcohol (V/V) of 6 times of amounts is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation, according to
It is secondary washed with absolute ethyl alcohol, acetone after, centrifuge；
Step 4：It is freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying,
Obtain ginseng wheat polysaccharide pulvis.
By two kinds of medicinal material residues according to 1 in embodiment 1：1 (w/w) ratio mixes, i.e., by distilled water according to solid-liquid ratio 1：30、
90 DEG C of temperature, twice, each 1h, merges concentrate to the 1/20 of former extracting liquid volume, filtration is spare for extraction；4 are added after concentration
The absolute ethyl alcohol (V/V) of amount again, 4 DEG C stand overnight, and precipitation is collected by centrifugation, after being washed successively with absolute ethyl alcohol, acetone, centrifugation point
From；The polysaccharide formulation polyoses content being experimentally verified that is up to 62.8%.
By red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1 in embodiment 2：1 (w/w) ratio mix, i.e., by distilled water according to
Solid-liquid ratio 1:20th, 100 DEG C of temperature, twice, each 0.5h, merges concentrate to the 1/20 of former extracting liquid volume, filtration is standby for extraction
With；The absolute ethyl alcohol (V/V) of 2 times of amounts is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation, successively with absolute ethyl alcohol, third
After ketone washing, centrifuge；The polysaccharide formulation polyoses content being experimentally verified that is up to 60.78%.
By red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1 in embodiment 3：1 (w/w) ratio mix, i.e., by distilled water according to
Solid-liquid ratio 1:40th, temperature 60 C, twice, each 1.5h, merges concentrate to the 1/20 of former extracting liquid volume, filtration is standby for extraction
With；The absolute ethyl alcohol (V/V) of 6 times of amounts is added after concentration, 4 DEG C stand overnight, and precipitation is collected by centrifugation, successively with absolute ethyl alcohol, third
After ketone washing, centrifuge；It is experimentally verified that the obtained polysaccharide formulation polyoses content of gained up to 61.36%.
It can be seen that by red ginseng medicinal material slag and ophiopogon medicinal material slag according to 1：1 (w/w) ratio mixes, by distilled water according to feed liquid
Than 1：30th, 90 DEG C of temperature, twice, each 1h, merges concentrate to the 1/20 of former extracting liquid volume, filtration is spare for extraction；Concentration
The absolute ethyl alcohol (V/V) of 4 times of amounts is added afterwards, and 4 DEG C stand overnight, and precipitation is collected by centrifugation, and are washed successively with absolute ethyl alcohol, acetone
Afterwards, it is a kind of method of example to centrifuge, and can obtain the highest polysaccharide formulation of content.Therefore should be according in example one
Extraction and alcohol precipitating method, can obtain the highest ginseng wheat polysaccharide powder of polyoses content.
Embodiment 4
Ginseng wheat polysaccharide is used in hypoimmunity mice by the present invention, for its Immune Organs Index, the intestine immunity factor
And the influence of intestinal flora has carried out following Efficacy experiments：
18-22g mouse 40 are chosen, are grouped into blank group, model group, high dose group and low dose group at random, are utilized
Endoxan builds the low model of mouse immune, by being injected intraperitoneally to the endoxan that mouse injection dosage is 60mg/kg, abdomen
A length of three days, wherein blank group injecting normal saline when chamber is injected.
Gavage, blank group and model group gavage physiological saline, high dose group intragastric administration on mice are carried out after the completion of modeling to mouse
Join wheat polysaccharide powder sample, dosage 100mg/kg, low dose group decimal gavage 50mg/kg ginseng wheat polysaccharide powder sample, gavage 7 days.
Mouse was weighed in second day after the completion of gavage, the neck that breaks is put to death, its solution is taken its spleen and thymus gland organ, is weighed
Computation immunity shoot formation after record, takes out mouse intestinal tissue, isolates mouse cecal content and ileal tissue, stores
It is spare.Wherein cecal content is used for the detection of intestinal flora, and ileal tissue is used for the detection of intestine immunity Protein S IgA.
Testing result shows that after modeling is carried out to mouse, its thymus gland and index and spleen index substantially reduce, it is filled
After stomach, high dose group mouse and the Thymus and Spleen index of low dose group mouse substantially increase.In index and spleen index result,
The value of dosage group apparently higher than model group, and between three groups there are significant difference, P ＜ 0.01, and high dose group apparently higher than
Low dosage, may indicate that high dose ginseng wheat polysaccharide powder plays the role of significantly strengthening immune organ.And in thymus index result,
Its dosage class value is apparently higher than model group, and there are significant difference, P ＜ 0.05, its effect are opposite between high dose group and model group
It is more notable in low dose group.Specifically it is shown in Table 1 and table 2.
By the measure to ileal tissue SIgA contents, testing result shows, ginseng wheat polysaccharide powder is obviously improved intestine immunity
The content of secretory protein SIgA, dosage group SIgA contents are apparently higher than model group, and there are significant difference between model group,
P ＜ 0.05.It may indicate that ginseng wheat polysaccharide powder can significantly improve hypoimmunity mice intestine immunity albumen to a certain extent
The content of SIgA.Specifically it is shown in Table 3.
The detection of intestinal flora result shows that after modeling, Bifidobacterium and Bacillus acidi lactici quantity are obvious in mouse intestinal
Reduce, there are significant difference, P ＜ 0.05 between blank group.After joining wheat polysaccharide powder gavage, its dosage group bifidobacteria is bright
Aobvious rise, and high dose group bifidobacteria higher.In Bacillus acidi lactici detection, dosage group Bacillus acidi lactici quantity is higher than model
Group, higher than blank group, and there are significant difference, P ＜ 0.05 between dosage group and model group and blank group.Pass through result above
Show, ginseng wheat polysaccharide powder is remarkably reinforced for the immune organ of hypoimmunity mice, and is significantly affected enteron aisle and exempted from
Epidemic disease, improves hypoimmunity mice intestine immunity ability.Specifically it is shown in Table 4.
Table 1 joins influence of the wheat polysaccharide to hypoimmunity mice index and spleen index
Note：There is otherness, P ＜ 0.05. between different letter expression groups in table
Table 3 joins influence of the wheat polysaccharide to hypoimmunity mice enteron aisle SIgA contents
Note：There is otherness, P ＜ 0.05. between different letter expression groups in table
Table 4 joins influence of the wheat polysaccharide to hypoimmunity mice intestinal flora
Note：There is otherness, P ＜ 0.05. between different letter expression groups in table
Some preferred embodiments of invention have shown and described in described above, but as previously described, it should be understood that invention is not
Form disclosed herein is confined to, is not to be taken as the exclusion to other embodiment, and available for various other combinations, modification
And environment, and can be carried out in the scope of the invention is set forth herein by the technology or knowledge of above-mentioned teaching or association area
Change., then all should be in power appended by invention and changes and modifications made by those skilled in the art do not depart from the spirit and scope of invention
In the protection domain that profit requires.
Claims (5)
1. the preparation method of a seed ginseng wheat polysaccharide formulation, it is characterised in that comprise the following steps：
Step 1, ethanol removal of impurities：Red ginseng and ophiopogon being separately added into alcohol dipping, then heating and refluxing extraction, red ginseng extracts 6 times,
Ophiopogon extracts 2 times, is extracted every time with 3 times of amount alcohol refluxs；Recycling extraction residue, dries in drier, red ginseng is prepared
Medicinal material slag and ophiopogon medicinal material slag；
Step 2, the contracting of water concentrate：Red ginseng medicinal material slag and ophiopogon medicinal material slag are mixed, distilled water is added and is extracted, extraction is twice；
Merge extracting solution and be concentrated into 1/20 volume, filter, concentrate is prepared, it is spare；
Step 3, alcohol precipitation：Absolute ethyl alcohol is added in the concentrate that step 2 is prepared, 4 DEG C stand overnight, and it is heavy to be collected by centrifugation
Form sediment, after being washed successively with absolute ethyl alcohol, acetone, centrifuge；
Step 4, be freeze-dried to obtain powder：Put the precipitate in freeze drying equipment, be milled after vacuum freeze drying, obtained
Join wheat polysaccharide pulvis.
2. the preparation method of ginseng wheat polysaccharide formulation according to claim 1, it is characterised in that the ethanol in the step 1
Volume fraction be 70%-90%；Extraction time is 1.5h-2.5h.
3. the preparation method of ginseng wheat polysaccharide formulation according to claim 1, it is characterised in that the red ginseng in the step 2
The mass ratio of medicinal material slag and ophiopogon medicinal material slag is 1:1；The gross mass and distilled water of the red ginseng medicinal material slag and ophiopogon medicinal material slag
Solid-liquid ratio (g/ml) is 1:20-1:40；Water temperature raising degree is 60-100 DEG C, and it is 0.5-1.5h that each water, which carries the time,.
4. the preparation method of ginseng wheat polysaccharide formulation according to claim 1, it is characterised in that the concentration in the step 3
The volume ratio of thing and absolute ethyl alcohol is 1:2-1:6.
A kind of 5. ginseng wheat polysaccharide formulation that preparation method as described in claim 1-4 any claims is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810075941.XA CN107998274B (en) | 2018-01-26 | 2018-01-26 | Ginseng and ophiopogon polysaccharide preparation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810075941.XA CN107998274B (en) | 2018-01-26 | 2018-01-26 | Ginseng and ophiopogon polysaccharide preparation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107998274A true CN107998274A (en) | 2018-05-08 |
| CN107998274B CN107998274B (en) | 2021-05-28 |
Family
ID=62066421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810075941.XA Expired - Fee Related CN107998274B (en) | 2018-01-26 | 2018-01-26 | Ginseng and ophiopogon polysaccharide preparation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998274B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969649A (en) * | 2018-09-17 | 2018-12-11 | 四川农业大学 | One seed ginseng wheat polyoses oral liquid and preparation method thereof |
| CN110423286A (en) * | 2019-08-30 | 2019-11-08 | 鲁南制药集团股份有限公司 | A kind of extracting method and application thereof of Chinese medicine dreg polysaccharide |
| CN112830977A (en) * | 2021-02-26 | 2021-05-25 | 西南科技大学 | Method for extracting and purifying polysaccharide from fibrous root residues of radix ophiopogonis |
| CN114668075A (en) * | 2022-04-20 | 2022-06-28 | 四川农业大学 | Ginseng and wheat fibrous root polysaccharide granules and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596954A (en) * | 2004-09-24 | 2005-03-23 | 贵阳云岩西创药物科技开发有限公司 | Red ginseng and ophiopogon root preparation and its making method |
-
2018
- 2018-01-26 CN CN201810075941.XA patent/CN107998274B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596954A (en) * | 2004-09-24 | 2005-03-23 | 贵阳云岩西创药物科技开发有限公司 | Red ginseng and ophiopogon root preparation and its making method |
Non-Patent Citations (2)
| Title |
|---|
| 方三华: "参麦有效部位抗肿瘤作用的实验研究", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑》 * |
| 胡闻莉等: "生脉散多糖的组成及其初级结构分析", 《中国药科大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969649A (en) * | 2018-09-17 | 2018-12-11 | 四川农业大学 | One seed ginseng wheat polyoses oral liquid and preparation method thereof |
| CN110423286A (en) * | 2019-08-30 | 2019-11-08 | 鲁南制药集团股份有限公司 | A kind of extracting method and application thereof of Chinese medicine dreg polysaccharide |
| CN112830977A (en) * | 2021-02-26 | 2021-05-25 | 西南科技大学 | Method for extracting and purifying polysaccharide from fibrous root residues of radix ophiopogonis |
| CN114668075A (en) * | 2022-04-20 | 2022-06-28 | 四川农业大学 | Ginseng and wheat fibrous root polysaccharide granules and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107998274B (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107998274A (en) | One seed ginseng wheat polysaccharide formulation and preparation method thereof | |
| CN108752497A (en) | Prepared by Morinda officinalis water extract, oligosaccharides and polysaccharide, and its application | |
| KR20100022539A (en) | The composition of drug for improvement of impotency and circulation of blood | |
| CN102552644A (en) | Anti-tumor use, preparation method and composition of garlic total polysaccharide | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN101243882B (en) | Health food with function of reducing blood fat and its preparation | |
| CN112401239A (en) | Composition for reducing blood sugar and preparation method and application thereof | |
| CN105617355A (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN105362285A (en) | Method for preparing compound polysaccharides having effect of promoting gastric emptying and application of compound polysaccharides | |
| CN1895546B (en) | Lycium chinensis polyose medicinal composition with therapeutic and health-care functions | |
| CN102408494A (en) | Grifola frondosa polysaccharide ZZK component and preparation method thereof | |
| CN114796357A (en) | Astragalus root body resistance strengthening tea with function of regulating immunity and preparation method thereof | |
| CN106728208A (en) | A kind of ginseng and lucid ganoderma polysaccharide triterpene preparation and preparation method thereof | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN112755044B (en) | Pharmaceutical composition for reducing blood sugar, preparation method and application | |
| CN114848786A (en) | Compound Sanshen decoction for resisting cancer and increasing immunity | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
| CN103169844B (en) | Traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects | |
| CN105412613A (en) | Composition for Alzheimer's disease and processing method of composition | |
| CN105343206B (en) | Compound traditional Chinese medicine extract for reducing blood pressure and blood fat and preparation method thereof | |
| CN100441197C (en) | Medicinal composition containing panax ginseng polysaccharide | |
| CN104146244B (en) | Not old careless oral liquid of a kind of wilsonii and preparation method thereof | |
| CN108853337A (en) | A kind of herbal cuisine and preparation method thereof for Cancer related fatigue to be mitigated or eliminated | |
| CN105963356A (en) | Anti-hepatitis medicine | |
| CN101695543B (en) | Composition for treating arrhythmia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210528 Termination date: 20220126 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |